Evidence map›Paper›PMID 42251441›Full record

ArticleArchives of public health = Archives belges de sante publique2026

The Chile BiLS case-control study of gallbladder cancer.

Jill Koshiol, Vanessa Van De Wyngard, Ilona Argirion, Claudia Marco, Matías A Pozo Diaz, Ian N Reyes Romero, Paz Cook, Ruth M Pfeiffer, Noldy Mardones, Karie Medina and 12 more

Abstract read
In one paragraph

Article in Archives of public health = Archives belges de sante publique, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jill KoshiolDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. koshiolj@mail.nih.gov.ORCID http://orcid.org/0000-0002-3832-6204
Vanessa Van De WyngardFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Ilona ArgirionDepartment of Human Science, School of Health, Georgetown University Medical Center, Washington, DC, USA.ORCID http://orcid.org/0000-0002-4925-5296
Claudia MarcoFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID http://orcid.org/0000-0002-3631-8817
Matías A Pozo DiazFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID http://orcid.org/0009-0001-5940-075X
Ian N Reyes RomeroFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID http://orcid.org/0009-0006-8439-0350
Paz CookFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Ruth M PfeifferDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Noldy MardonesHospital Dr. Hernan Henríquez Aravena, Temuco, Chile.
Karie MedinaHospital Dr. Hernan Henríquez Aravena, Temuco, Chile.
Vanessa OlivoWestat, Inc., Rockville, MD, USA.
Karen PettitWestat, Inc., Rockville, MD, USA.
Raúl SanchezFacultad de Medicina, Universidad de La Frontera, Temuco, Chile.
Miguel VillasecaHospital Dr. Hernan Henríquez Aravena, Temuco, Chile.
Enrique BellolioFacultad de Medicina, Universidad de La Frontera, Temuco, Chile.
Hector LosadaHospital Dr. Hernan Henríquez Aravena, Temuco, Chile.
Juan Carlos RoaFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Allan HildesheimAgencia Costarricense de Investigaciones Biomedicas, San Jose, Costa Rica.ORCID http://orcid.org/0000-0003-0257-2363
Marco AresseFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Catterina FerreccioFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID http://orcid.org/0000-0001-6331-5534
Juan Carlos ArayaHospital Dr. Hernan Henríquez Aravena, Temuco, Chile. jcaorostica@gmail.com.ORCID http://orcid.org/0000-0003-3501-8203
Chile BiLS Study Group

Funding

Comisión Nacional de Investigación Científica y Tecnológica for the Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias 15130011Fondo Nacional de Desarrollo Científico y Tecnológico 1170395
6 · The paper itself

Abstract

backgroundGallbladder cancer (GBC) is highly fatal and, unlike most cancers, is more common in women than in men. Most GBC cases have gallstones, but most people with gallstones do not develop GBC. Thus, a critical question is what drives the risk of GBC in the presence of gallstones.

methodsWe designed a case-control study to complement the Chile Biliary Longitudinal Study (Chile BiLS) cohort, enriching the number of GBC cases and enhancing our ability to evaluate risk factors for GBC. Starting in July 2022, we began to recruit non-cohort prevalent (diagnosed between January 1, 2016, and July 18, 2022) and incident (diagnosed on or after July 19, 2022) GBC cases, as well as patients with high-grade dysplasia (HGD), in a high-risk area of Chile. Individuals with GBC or HGD are considered cases (HGD +). We are matching gallstone cholecystectomy patients to cases at an approximate 1:1 ratio. We also include unmatched controls (adjudicated) who were initially suspected of having cancer but had benign findings on gallbladder pathology. If a case or control is deceased, we conduct proxy interviews to maximize the potential for detailed epidemiological data collection. Through August 31, 2025, we recruited 196 prevalent and 117 incident HGD + cases. Of these cases, 189 (96%) prevalent and 108 (92%) incident cases were diagnosed with GBC. All prevalent and 98.3% of incident cases have matched controls. Participation rates are 70.8% for HGD + cases and 67.8% for matched controls. DISCUSSION: The Chile BiLS case-control study is conducted in an area with high risk of GBC and a high proportion of people with Mapuche Amerindian ancestry. This study will provide important insights into the factors associated with GBC among people with gallstones. Here, we provide a thorough description of the design of the study, field procedures, and biological resources, as well as research opportunities, which will enable a more complete picture of the etiology of GBC by combining epidemiological, molecular, digital imaging, and clinical data. This study represents a powerful resource for the identification of new targets for cancer prevention and treatment, which are particularly needed in populations at high risk of GBC.

Indexed as

Early detectionEtiologyGallbladder cancerHigh-grade dysplasiaMolecular epidemiology

Identifiers

PMID42251441
PMCPMC13463823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.